| Clinical study "common" name (formal title) | Number of enrollees (per protocol [PP]/intent-to-treat [ITT]) | Funding source (pharmaceutical company/National Institutes of Health [NIH]) | Year completed | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
| PLANET (Aflibercept in Polypoidal Choroidal Vasculopathy) | 318 patients | Bayer/Regeneron NCT02120950 | 2016 | Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial [published correction appears in JAMA Ophthalmol. 2018;136(7):840]. JAMA Ophthalmol. 2018;136(7):786-793. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2680578 |
|